Skip to main content

Current Clinical Trials

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers.  They are also called “participants.”  Clinical Trials FAQs.

Find a Clinical Trial

Therapeutic Area Condition  Study
Number
Description Status
(click on link to learn more) 
Haematology & Thrombosis
Hemophilia A OPERA Register of Patients With haEmophilia A tReated With Afstyla® (OPERA) Active, Not Recruiting
  Hemophilia B OrPHEe Observatory of Patients With Haemophilia B Treated by IdElvion® Recruiting 
  Sickle Cell CSL889_1001 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease
Recruiting
  Von Willebrand Disease
OPALE Registry of Patients With Von WilLEbrand Disease Treated With Voncento® (OPALE)
Active, Not Recruiting
Cardiovascular and Metabolic Acute Coronary Syndrome CSL112_3001 Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) Recruiting
  Diabetic Kidney Disease CSL346_2001 A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease  Recruiting 
Immunology and Neurology  Dermatomyositis (DM) IgPro20_3007 A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) [RECLAIIM] Recruiting
  Pediatric CIDP IgPro10_4002 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting
  Hereditary Angioedema (HAE)
CSL312_3001 CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks Active, Not Recruiting 
  Hereditary Angioedema (HAE)
CSL312_3002 Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Recruiting 
  Hidradenitis Suppurativa and Palmoplantar Pustulosis CSL324_1002 A study of the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis Recruiting
  Inflammatory Neuropathy pHeNIx
Hizentra® in Inflammatory Neuropathies - pHeNIx Study Suspended
  Systemic Sclerosis IgPro20_2001 A study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc). Active, Not Recruiting
  Healthy Subjects CSL730_1002 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects Recruiting 
 Respiratory Mild Asthma CSL311_1001 A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. Active, Not Recruiting
  Idiopathic Pulmonary Fibrosis CSL312_2002 CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis Recruiting
  Non-cystic Fibrosis Bronchiectasis (NCFB)
CSL787_1001 Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) Recruiting 
  alpha-1 antitrypsin deficiency
AmAREtTI Study
Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)
Recruiting
Transplant Antibody-mediated kidney transplant rejection CSL300_3001 A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients [IMAGINE] Recruiting
  Acute GVHD (aGVHD) CSL964_2001 The Safety and Efficacy of Alpha 1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant [MODULATE] Recruiting
  Graft Versus Host Disease (GVHD) CSL964_5001 A study on the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD Recruiting

 

COMPLETED STUDIES:

COVID-19 COVID-19 CSL312_COVID-19 A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) Results
  COVID-19 CSL324_COVID-19 CSL324 in COVID‑19 Withdrawn
  COVID-19 CSL760_1001 Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects Cancelled
Haematology & Thrombosis
Reversal of acquired coagulation factor deficiency BE1116_4001
An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
Completed

Congenital Fibrinogen Deficiency BI3023_4003 An Observational Study of the Safety and Efficacy of Fibrinogen Concentrate Human (FCH) in Subjects With Congenital Fibrinogen Deficiency  Completed
  Hemophilia A
CSL627_3001  An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Results 
  Hemophilia B  CSL654_3001 A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Results
  Hemophilia B  CSL654_3002 A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
Results 
  Hemophilia B CSL654_3003 A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Completed
  Hemophilia A or B CSL689_2001 Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors  Cancelled 
  PICC-associated Thrombosis
CSL312_1002
A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line  Withdrawn
  Sickle Cell CSL200_1001 CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
Cancelled
Von Willebrand Disease CSLCT-BIO-12-83 Study of Voncento® in Subjects With Von Willebrand Disease Completed
Cardiovascular and Metabolic Coronary Heart Disease CSL112_1001 Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Completed
  Renal Impairment and Acute Myocardial Infarction CSL112_2001 A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction Results
  Acute Myocardial Infarction CSLCT-HDL-12-77
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
Results
Immunology and Neurology
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20_3004
Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Results
  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
IgPro10_5004
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)
Cancelled

Hereditary Angioedema (HAE) CSL312_2001
A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
Completed

Hereditary Angioedema (HAE)
CSL830_2001 A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route
Results 

Hereditary Angioedema (HAE)
CSL830_3001 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Results
  Hereditary Angioedema (HAE)  CSL830_3002 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Results

Hereditary Angioedema (HAE)
CSL830_3003
A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects
Results
  HIV-1 CAL-USA-11 An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART Results
  Primary Immune Deficiency (PID) IgPro20_1001 Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump Results
  Primary Immune Deficiency (PID) IgPro20_4004 Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) Results
  Primary Immune Deficiency (PID) IgPro20_4005 Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (Hizentra®) on Weekly and Biweekly Schedules Results
  Systemic Sclerosis IgPro10_2001 Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis Withdrawn
  Healthy Subjects CSL312_1003 A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults Completed
  Healthy Subjects CSL324_1001 Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Completed
  Healthy Subjects CSL324_1003 Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Completed 
  Healthy Subjects CSL730_1001 Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults
Cancelled
Transplant Antibody-mediated kidney transplant rejection CSL842_3001 Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients Cancelled